Fennec Pharmaceuticals (FENC) Short term Debt (2021 - 2022)
Fennec Pharmaceuticals' (FENC) quarterly Short term Debt came in at $25.0 million in Q4 2022, up 1263.88% YoY from $1.8 million in Q4 2021, and up 2400.0% on a QoQ basis from $1.0 million in Q2 2022.
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Short term Debt (2021 - 2022) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 2 years of Short term Debt data on file, last reported at $25.0 million in Q4 2022.
- Quarterly Short term Debt rose 1263.88% year-over-year to $25.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $25.0 million (up 1263.88% YoY) and the FY2022 annual result came in at $25.0 million, up 1263.88% from the prior year.
- Short term Debt rose to $25.0 million in Q4 2022, from $1.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $25.0 million in Q4 2022 to a low of $500000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 25.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | 2.00 Mn |
| Jun 30, 2021 | 2.00 Mn |